ACE inhibitors were also discontinued in patients with chronic coronary syndromes or heart failure based on initial speculations that the use of ACE inhibitors, leading to increased expression of ACE2, which could potentially facilitate infection with COVID-19. This evidence concerns the gene ACE and COVID-19.